For the -month periods ended and our total stock-based compensation expense, which includes reversals of expense for certain forfeited or cancelled awards, was approximately and respectively. We have recorded any income tax benefit related to stock-based compensation in either of the -month periods ended and

 

A summary of the status of our stock options as of and changes during the -month period then ended, is presented below.

 

		T hree Months Ended March 31, 20 20
		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Life (years)				Aggregate Intrinsic Value
Outstanding at beginning of period			238,470			$	17.38				7.2			$	—
Granted			195,000				1.06
Exercised			—				—
Canceled and Forfeited			(1,500	)			1.06
Expired			(500	)			30.80
Outstanding at end of period			431,470			$	10.04				8.3			$	—
Exercisable at end of period			112,290			$	25.54				5.7			$	—

 

A summary of the status of our unvested restricted stock as of and changes during the -month period then ended, is presented below.

 

		Three Months Ended March 31, 20 20
		Number of Shares				Weighted Average Grant-Date Fair Value
Unvested at beginning of period			15,000			$	2.75
Granted			10,000				1.06
Vested			(15,000	)			2.75
Forfeited			—				—
Unvested at end of period			10,000			$	1.06

 

As of there was approximately of total unrecognized compensation expense related to unvested stock-based awards, which we expect to recognize over the remaining weighted average vesting term of years.